StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultNov 2, 2026, 04:02 PM

Syndax Pharmaceuticals 3Q26 Revenue $83.3M (+82% YoY); Revuforj Sales $60.7M

AI Summary

Syndax Pharmaceuticals reported strong third-quarter 2026 financial results, with total revenue surging 82% year-over-year to $83.3 million. Revuforj® (revumenib) net revenue grew 90% to $60.7 million, driven by a 20% increase in new patients. Niktimvo™ (axatilimab-csfr) contributed $22.6 million in collaboration revenue. The company also announced the upcoming retirement of its CFO, Keith Goldan, and the appointment of Aaron A. Ondrey as his successor. Despite increased R&D expenses, the net loss narrowed compared to the prior year.

Key Highlights

  • Syndax Pharmaceuticals reported 3Q26 total revenue of $83.3 million, an 82% year-over-year increase.
  • Revuforj® (revumenib) net revenue reached $60.7 million in 3Q26, up 90% year-over-year, with a 20% increase in new patients.
  • Niktimvo™ (axatilimab-csfr) net revenue was $67.4 million in 3Q26, a 47% year-over-year increase, contributing $22.6 million in collaboration revenue to Syndax.
  • Research and development expenses increased to $67.5 million in 3Q26 from $56.3 million in 3Q25.
  • Selling, general and administrative expenses decreased to $43.7 million in 3Q26 from $44.9 million in 3Q25.
  • Net loss for 3Q26 was $49.4 million, or $0.55 per share, compared to a net loss of $60.7 million, or $0.70 per share, in 3Q25.
  • Company ended 3Q26 with $551.1 million in cash, cash equivalents, and investments.
  • Keith Goldan will retire as CFO; Aaron A. Ondrey appointed as new CFO, effective November 9, 2026.